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Abstract
Background: Hormone therapy, oral contraceptives, and tamoxifen increase the risk of
thrombotic disease. These compounds also reduce plasma content of tissue factor pathway
inhibitor-1 (TFPI), which is the physiological inhibitor of the tissue factor pathway of coagulation.
The current aim was to study if estrogens and estrogen receptor (ER) modulators may inhibit TFPI
production in cultured endothelial cells and, if so, identify possible mechanisms involved.
Methods: Human endothelial cell cultures were treated with 17β-estradiol (E2), 17α-
ethinylestradiol (EE2), tamoxifen, raloxifene, or fulvestrant. Protein levels of TFPI in cell media and
cell lysates were measured by an enzyme-linked immunosorbent assay, and TFPI mRNA levels were
assessed by quantitative PCR. Expression of ERα was analysed by immunostaining.
Results: All compounds (each in a concentration of 10 nM) reduced TFPI in cell medium, by 34%
(E2), 21% (EE2), 16% (tamoxifen), and 28% (raloxifene), respectively, with identical inhibitory
effects on cellular TFPI levels. Expression of TFPI mRNA was principally unchanged. Treatment
with fulvestrant, which was also associated with down-regulation of secreted TFPI (9% with 10 nM
and 26% with 1000 nM), abolished the TFPI-inhibiting effect of raloxifene, but not of the other
compounds. Notably, the combination of 1000 nM fulvestrant and 10 nM raloxifene increased TFPI
secretion, and, conversely, 10 nM of either tamoxifen or raloxifene seemed to partly (tamoxifen)
or fully (raloxifene) counteract the inhibitory effect of 1000 nM fulvestrant. The cells did not
express the regular nuclear 66 kDa ERα, but instead a 45 kDa ERα, which was not regulated by
estrogens or ER modulators.
Conclusion: E2, EE2, tamoxifen, raloxifene, and fulvestrant inhibited endothelial production of
TFPI by a mechanism apparently independent of TFPI transcription.
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Hormone therapy (HT) [1-4], oral contraceptives (OCs)
[5,6], raloxifene[7] and tamoxifen[8] are all associated
with increased risk of venous thromboembolism (VTE).
HT [9] and OCs [10,11] also increase the risk of arterial
thrombosis. The mechanism(s) by which these drugs may
cause thrombotic diseases is not fully understood. They
are thought to induce "acquired" resistance to activated
protein C[12,13] and also change plasma contents of sev-
eral coagulation factors and coagulation inhibitors, which
assumingly may alter the "haemostatic balance" in a pro-
thrombotic direction [14,15].
The therapeutic action of HT, OCs, raloxifene, and
tamoxifen is mediated by the estrogen receptor-α (ERα).
The estrogen component of OCs is 17α-ethinylestradiol
(EE2), whereas HT contains either 17β-estradiol (E2) or
conjugated equine estrogens. While E2 and EE2 are strong
ER agonists, raloxifene and tamoxifen are defined as selec-
tive ER modulators (SERMs). Raloxifene is a relatively
new drug for treatment of osteoporosis, whereas
tamoxifen for several decades has been used as first-line
anti-hormonal therapy for ER-positive breast cancer in
premenopausal patients. These compounds show tissue-
specific agonistic or antagonistic effects. Recently, fulves-
trant was approved as a novel breast cancer anti-estrogen.
This compound belongs to a class of drugs termed selec-
tive ER down-regulators (SERDs), which have been
claimed to be completely devoid of agonistic effects[16].
Tissue factor pathway inhibitor-1 (TFPI) is mainly pro-
duced by the endothelium [17] and is the physiological
inhibitor of the tissue factor pathway of blood coagula-
tion. This pathway is considered to be the principal initi-
ator of coagulation [18]. TFPI binds both to activated
factor X (FXa) and the activated factor VII (FVIIa)/tissue
factor complex to build an inert quaternary complex, and
thereby inhibits FXa as well as the TF/FVIIa complex. Low
levels of circulating TFPI in plasma have been shown to
double the risk for both venous[19] and arterial[20]
thrombosis. Moreover, TFPI may be involved in angiogen-
esis[21] and contribute to the anti-angiogenic properties
of heparins[22].
Tamoxifen[23], HT [24], and OCs[19,25] all reduce
plasma concentration of TFPI. Furthermore, TFPI levels in
premenopausal women are lower than in men and post-
menopausal women. This suggests that estrogens or drugs
mimicking effects of estrogens may reduce the production
of TFPI, either by a direct effect on the endothelium or
indirectly through other mechanisms.
The mechanism by which ER-binding drugs regulate TFPI
is largely unknown. We hypothesized that E2, EE2,
raloxifene, and tamoxifen might inhibit endothelial TFPI
production by an ER-mediated genomic mechanism (via
inhibition of TFPI mRNA expression) and that fulvestrant
might counteract any inhibitory effect, i.e., that the effects
on TFPI production might be classically ER-dependent.
However, all tested compounds (estrogens, SERMs, and,
interestingly, also fulvestrant) were found to down-regu-
late endothelial TFPI production, both in cell medium
and in whole cell lysates, by a mechanism apparently
independent of TFPI transcription.
Methods
Reagents
Before start of experiments, cells were cultured in growth
medium containing EBM-2 basal medium (#CC-3156)
supplemented with EGM-2-MV SingleQuots and growth
factors (#CC-4147) in addition to 10% FCS (#DE14-
801F). The experiments were performed in hormone-defi-
cient medium containing EBM phenol red-free medium
(#CC-3129) with 10% charcoal/dextran-stripped FCS
(#14-820F), and supplemented with EGM-2 MV Sin-
gleQuots and growth factors (#CC-4147) minus hydro-
cortisone. All cell media and FCS were purchased from
Cambrex Bio Science, Walkersville, MD, USA. E2
(#E2758), EE2 (#E4876), raloxifene hydrochloride
(#R1402) and tamoxifen (#T5648) were purchased from
Sigma. Fulvestrant (#1047), also termed ICI 182,780, was
purchased from Tocris BioScience, Ellisville, MO, USA.
Cell cultures and study design
Human coronary artery endothelial cells (HCAEC, #CC-
2585) that had been isolated from single-donor, normal
human tissue and cryopreserved in endothelial cell
media, were purchased from Cambrex Bio Science, Walk-
ersville, MD, USA. In our experiments, cells from both
female and male donors were used. The cells were cul-
tured in growth medium for three days, then trypsinated
onto a 24-well plate and left overnight in growth medium
before experimental procedures. At this stage the HCAEC
were at passage seven. Human umbilical cord vascular
endothelial cells (HUVEC) were isolated from veins of
umbilical cords obtained from newborns after normal
pregnancies, according to the method of Jaffe et al[26].
Isolated single-donor HUVEC were immediately seeded
onto 24-well plates and left overnight in growth medium
before experiments were performed, i.e., the HUVEC were
at passage one.
Experimental procedures: HUVEC were preincubated in
triplicates with hormone-deficient medium only (con-
trols) or with hormone-deficient medium containing E2
(0.1–10 nM) for 48 h. Similarly, HCAEC were preincu-
bated in triplicates for 48 h with hormone-deficient
medium only (controls) or with hormone-deficient
medium containing E2, EE2, tamoxifen, raloxifene, or ful-
vestrant (each 10 nM). To study any counteracting effectsPage 2 of 9
(page number not for citation purposes)
BMC Cardiovascular Disorders 2006, 6:40 http://www.biomedcentral.com/1471-2261/6/40of SERD, fulvestrant (1000 nM) was added to control
medium or the media containing each of the other com-
pounds. After the preincubation, when the cells were 80%
confluent, the experimental media were exchanged to new
drug-containing media for additional 24 h before cell har-
vesting, i.e., the total incubation time in experimental
media was 72 h.
Assays of TFPI antigen and total protein
TFPI total antigen was assayed in duplicates with a com-
mercial enzyme-linked immunosorbent assay (Asser-
achrom® Total TFPI, Diagnostica Stago, Asnière, France)
described in detail elsewhere[19]. Cellular total protein
was measured by an improved Lowry assay (Bio-Rad DC
Protein Assay, Bio-Rad Laboratories, Hercules, CA, USA).
Levels of TFPI total antigen secreted into cell media and in
whole cell lysates were normalised against the cellular
total protein content of each sample.
Relative quantification of TFPI mRNA
Cellular TFPI mRNA levels were determined by quantita-
tive real-time RT-PCR (qRT-PCR) analysis (ABI PRISM
7700 Sequence Detection System, Applied Biosystems,
Foster City, CA, USA). Primers and probes were designed
using Primer Express software version 2.0 (Applied Bio-
systems, Foster City, CA, USA) and purchased from Med-
probe (Eurogentec, 4102 Seraing, Belgium). Their
sequences were: 5'-ACACACAATTATCACAGATACG-
GAGTT-3' (forward primer), 5'-TTCAAGGCGGATGAT-
GGC-3' (reverse primer) and 5'-
CCACCACTGAAACTTATGCATTCATTTTGTGC-3'
(probe). Total RNA was isolated from lysed cells using the
ABI PRISM 6100 Nucleic Acid Prep Station (Applied Bio-
systems, Foster City, CA, USA) according to the manufac-
turer's recommendations. The procedure included a step
with DNAse I treatment (Applied Biosystems, Foster City,
CA, USA). Total RNA was quantified by ND-1000 (Nano-
Drop Technologies, Delaware, USA), and RNA quality was
checked by running an aliquot at RNA 6000 Nano
LabChip® on the 2100 Bioanalyzer (Agilent Technologies,
CA, USA). 100–300 ng of total RNA were reversely tran-
scribed using pd(N)6 random primers (First strand cDNA
synthesis kit, Amersham Biosciences, Little Chalfont
Buckinghamshire, Germany). qRT-PCR was performed
using the TaqMan® Universal Master mix (Applied Biosys-
tems, Foster City, CA, USA) containing 2 μL cDNA, 300
nM of each primer and 200 nM probe in a 25 μL final vol-
ume. The reactions were carried out in triplicate in Micro-
Amp Optical 96-well plates covered with MicroAmp
Optical Caps (Applied Biosystems, Foster City, CA, USA).
The PCR program was 50°C for 2 min, 95°C for 10 min,
40 cycles of 95°C for 15 sec, and 60°C for 1 min. Relative
mRNA levels were obtained by the comparative threshold
method (2^-ΔΔCt method) (User bulletin no. 2, Applied
Biosystems) and normalised to 18S RNA levels to com-
pensate for variations in input of RNA amounts. Levels of
18S RNA was not affected by any of the drugs in the exper-
iments.
Immunostaining
Cells grown in 6-well plates were either harvested when
culturing in growth medium for three days was com-
pleted, or treated identically as cell cultures used for TFPI
analyses. Cell pellets were lysed in 1 mL ice-cold lysis
buffer (M-PER Mammalian Protein Extraction Reagent
#78501, PIERCE, Rockford, IL, USA), to which 10 μL pro-
tease inhibitor cocktail (PIERCE, Rockford, IL, USA) and
10 μL 0.5 M EDTA #ED2SS (Sigma-Aldrich, St. Louis, MO,
USA) were added, mixed and incubated for 60 min at
4°C. The lysates were cleared by centrifugation for 30
min. Aliquots of 30 μg of total protein were separated on
an 8% SDS-polyacrylamide gel and analysed by standard
Western blot technique. The membranes were immunos-
tained with a mouse monoclonal antibody to ERα (SC-
8002; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), and with normal nonspecific mouse IgG (SC-2025;
Santa Cruz Biotechnology), and with an anti-α-tubulin
antibody (CP06; Calbiochem/Merck Biosciences, Ltd.,
Nottingham, UK). Immune complexes were detected with
horseradish peroxidase-coupled polyclonal rabbit anti-
mouse IgG (P0260, Dako, Glostrup, Denmark), and
enzyme activity was visualised with enzyme-linked
chemiluminescence (Amersham Biosciences, Ltd., Buck-
inghamshire, UK).
Competition studies were performed with a blocking pep-
tide (SC-8002P; Santa Cruz Biotechnology). The peptide
was preincubated with the anti-ERα antibody (SC-8002)
for 24 h in 4°C before use.
Statistics
The protein results were expressed as mean and standard
deviation (SD) and tested for statistical significance with
Student's two-tailed t-test. The PCR results were expressed
as mean and SD and tested for statistically significance
with the Relative Expression Software Tool (REST©) [27].
p ≤ 0.05 was considered statistically significant.
Results
Down-regulation of TFPI by E2 in HUVEC
HUVEC were incubated with increasing concentrations of
E2 (0.1–10 nM) and TFPI production was analysed. As
seen from Figure 1A, TFPI secreted to the medium was sig-
nificantly reduced by 16% (0.1 nM E2), 20% (1 nM E2),
and 12% (10 nM E2), respectively. Although TFPI mRNA
expression was reduced by 14% (0.1 nM E2), 18% (1 nM
E2), and 12% (10 nM E2) compared to control, these
effects were not statistically different from the control con-
dition (Figure 1B).Page 3 of 9
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In HCAEC, treatment with E2 (0.1–10 nM) reduced TFPI
in the medium by 25% (0.1 nM), 26% (1 nM), and 20%
(10 nM), but with no apparent change in transcription
(data not shown). Furthermore, both estrogens (E2 and
EE2) as well as SERMs (raloxifene and tamoxifen), each at
a concentration of 10 nM, significantly inhibited TFPI
protein production (Figure 2). Secreted TFPI was down-
regulated by 34% (E2), 21% (EE2), 28% (raloxifene), and
16% (tamoxifen) compared to control cells, and corre-
sponding results were obtained for cellular TFPI levels.
The pure ER antagonistic compound fulvestrant was also
included in this drug screen, and, notably, an inhibitory
effect on the protein level of TFPI was observed. Com-
pared to the control condition, 10 nM fulvestrant reduced
TFPI secretion by 9%, whereas 1000 nM caused down-reg-
ulation by 26% (Figure 2). Again, TFPI mRNA expression
in treated cells was not significantly different from that of
control cells (Figure 3). In a single experiment, the effect
of E2 (10 nM) on TFPI mRNA was followed every 8 h for
a total period of 72 h, but without any convincing, timed-
dependent change in the mRNA level (data not shown).
Fulvestrant antagonised the inhibitory effect of raloxifene 
on TFPI
Fulvestrant acts by down-regulating ER expression and is
principally devoid of agonistic effects. Hence, we investi-
gated if fulvestrant might counteract the inhibition of
TFPI production in HCAEC elicited by the other com-
pounds. Compared with each of the other drugs alone (at
concentrations of 10 nM), concurrent treatment with ful-
vestrant (1000 nM) fully antagonised the inhibitory effect
of raloxifene, resulting in net increased TFPI secretion. The
inhibitory effects of the other agents, however, were not
significantly changed (Figure 2). On the other hand, 10
nM of tamoxifen and raloxifene seemed to fully
(raloxifene) or partly (tamoxifen) antagonise the effects of
1000 nM fulvestrant alone (Figure 2, grey bars in TAM and
RAL groups are significantly different from grey bar in FUL
group).
ERα of the human endothelial cell cultures
Expression of ERα was analysed in both HCAEC and
HUVEC before start and after completion of incubation
with the various ER ligands. As seen from Figure 4,
HCAEC were devoid of 66 kDa ERα, but instead expressed
low levels of a 45 kDa ERα band both before and after
drug treatment. Interestingly, the 45 kDa ERα was not reg-
ulated by any of the ligands. Normal IgG from mouse did
not produce the 45 kDa band, and a competing peptide
removed the 45 kDa band from the western blot. An iden-
tical 45 kDa ERα protein species was found in HUVEC
before and after drug treatment (data not shown). No dif-
ference in ERα expression in the HCAEC from female or
male donors was seen (Figure 4).
Discussion
The present study showed that treatment of human
endothelial cell cultures with E2, EE2, tamoxifen,
raloxifene, or fulvestrant inhibited cellular TFPI produc-
tion, by a mechanism that apparently did not involve TFPI
transcription. These results experimentally support
recently reported observations that tamoxifen, HT, and
OCs reduce plasma concentration of TFPI in women
[19,23-25]. To our knowledge, this report is the first to
demonstrate that raloxifene and fulvestrant inhibit
endothelial TFPI production, suggesting that also these
compounds may cause lowering of plasma TFPI concen-
tration upon therapeutic utilization.
Our results confirm the conclusion by Bilsel et al, who
found E2-dependent reduction in secreted TFPI by
HUVEC[28]. Moreover, Shirk et al observed that EE2
Effects of E2 on secreted TFPI and TFPI mRNA expression in HUVECFigure 1
Effects of E2 on secreted TFPI and TFPI mRNA 
expression in HUVEC. The cells were incubated in the 
absence (controls) or presence of E2 (0.1–10 nM). Figure 1A 
indicates percent change (mean ± SD) of secreted TFPI in the 
media compared to controls, figure 1B shows fold change 
(mean ± SD) in TFPI mRNA compared to controls. The 
results are from two independent experiments. * is p < 0.01 
and # is p = 0.05 compared to control wells.
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manage to reproduce Bilsel et al's findings in HUVEC[29].
We also had difficulties in reproducing those results until
we changed the study design to include 48 h preincuba-
tion with the compounds (see Material and Methods).
The endothelial effect of OC, HT, and ER modulators is
possibly the principal mechanism by which these com-
pounds regulate plasma TFPI in women. Our results also
suggest that the estrogen component of OCs and HT may
be responsible for the TFPI-lowering effect of these drugs.
Fulvestrant has been claimed to be completely devoid of
ER agonist effects[16]. Thus, it was somehow surprising to
find that fulvestrant treatment, similar to what was
observed with the other compounds, was associated with
reduced TFPI production, although the equimolar fulves-
trant concentration apparently showed weaker inhibitory
activity. Indeed, concurrent treatment with a high concen-
tration of fulvestrant seemed to fully antagonise the inhib-
itory effect of raloxifene, but not of the other ER ligands,
on TFPI secretion. Conversely, tamoxifen and raloxifene,
fully or partly, antagonised the effect of fulvestrant, i.e.,
SERMs and SERD antagonised each other. Shirk et al
found that fulvestrant had no direct effect on TFPI in rats,
but counteracted the TFPI-lowering effect of EE2[29]. In
general, endothelial ER agonist effects are reversed by ful-
vestrant[30,31], although both E2, SERMs, and fulves-
trant may act synergistically, e.g., by inhibiting neointimal
thickening in rat [32]. It might be, at least in human blood
coagulation, that fulvestrant exerts dual actions; i.e., ago-
nistic when used as single agent but occasionally antago-
nistic to that function upon combinational treatment
with SERMs.
TFPI levels in cell medium and whole cell lysates were
similarly regulated by the various ER-ligands, which indi-
cate that regulation does not involve cellular secretion of
TFPI. Furthermore, cellular TFPI mRNA expression did
not seem to be the target for ER-mediated regulation
(although we cannot completely rule out a decrease of
TFPI mRNA in HUVEC), which is consistent with lack of
an estrogen responsive element in the human TFPI pro-
moter[33] to mediate classical ER-directed responses. Our
data are supported by Shirk et al, who did not find reduc-
Effects of ER ligands on TFPI production in HCAECFigure 2
Effects of ER ligands on TFPI production in HCAEC. The cells were incubated in the absence (controls) or presence of 
10 nM each of E2, EE2, raloxifene (RAL), tamoxifen (TAM) or fulvestrant (FUL). The bars show TFPI in the media (black bars), 
in whole cell lysates (white bars), or in the media after concurrent treatment with 1000 nM fulvestrant (gray bars) and indicate 
percent change (mean ± SD) compared to controls. Results are from three independent experiments. * is p ≤ 0.05. §refers to 
comparisons between respective gray and black bars, where §ns is non significant difference and §* is p ≤ 0.01
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ity, in rats[29]. Since all compounds tested in our study
are ER ligands, it is reasonable to assume that the effect on
TFPI is mediated by ER. The cell cultures did not express
the regular 66 kDa ERα, but a 45 kDa ERα. Hence, one
might speculate that the regulation of TFPI involves post-
transcriptional effect(s) mediated by the amino-termi-
nally truncated 45 kDa version of ERα. This hypothesis is
supported by studies showing that truncated ERα medi-
ates non-genomic effects of ER ligands [34-36]. Alterna-
tively, it might be that ERβ, or the recently described
GPR30 [37], are involved in this regulatory pathway.
ER-modifying agents are shown to exert differential effects
on stability of their 66 kDa receptor protein[38,39]. Such
responses, termed autologous receptor regulation[40], are
dependent on intact DNA-binding function of the amino-
terminal ERα domain[41]. The observed absence of lig-
and-operated regulation of the endothelial amino-termi-
nal truncated 45 kDa ERα is in accordance with this
concept.
Moreover, the variety of biological effects elicited by ER-
binding ligands are also governed by tissue-specific
expression of ER cofactors and modifying signalling path-
ways implicated[42]. Within blood coagulation, indeed,
estrogen agonists and ER modulators might differentially
regulate endothelial expression and activation of factors
like thrombomodulin and plasminogen activator inhibi-
tor type 1 [43-45]. Unlike for SERMs [46], an unfavoura-
ble coagulation profile of fulvestrant has so far not been
reported.
Conclusion
The main findings in this study were that estrogens and ER
modulators, including fulvestrant, reduced endothelial
TFPI production possibly in absence of transcriptional or
secretional down-regulation of TFPI. Furthermore, fulves-
trant seemed to counteract the inhibitory effect of
raloxifene but not of the other compounds tested. Since
our cells did not express the regular 66 kDa ERα, but
instead a truncated 45 kDa ERα, we hypothesize that ER
ligands might regulate TFPI expression through the trun-
cated ERα with ligand specificity different from the classi-
cal, nuclear ERα. An additional interesting observation
Lack of ER ligand effects on TFPI-transcriptionFigure 3
Lack of ER ligand effects on TFPI-transcription. The cells were incubated in the absence (controls) or presence of 10 
nM each of E2, EE2, raloxifene (RAL), tamoxifen (TAM) or fulvestrant (FUL). The bars show mean (± SD) fold change in TFPI 
transcription in HCAEC. The results are from three independent experiments. ns is non significant compared to control wells.
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regulated by estrogens, SERMs or SERD.
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ERα expression in HCAECFigure 4
ERα expression in HCAEC. The Western blots depict ERα levels in HCAEC, isolated from a male (M) and a female (F) 
donor prior to initiation of ER ligand incubation as well as after completion of 72 h incubation in the absence (CNT) or pres-
ence of 10 nM each of E2, EE2, tamoxifen (TAM), raloxifene (RAL) or fulvestrant (FUL). A whole cell lysate of MCF7 cells was 
included as positive control and expression of α-tubulin was measured as loading control. Normal non-specific mouse IgG and 
a blocking peptide was included to ensure specificity of the bands.
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